CytomX Therapeutics (CTMX) Other Gross PP&E Adjustments (2016 - 2025)
CytomX Therapeutics (CTMX) has disclosed Other Gross PP&E Adjustments for 12 consecutive years, with -$5.5 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Other Gross PP&E Adjustments rose 48.94% year-over-year to -$5.5 million, compared with a TTM value of -$5.5 million through Sep 2025, up 48.94%, and an annual FY2024 reading of $9.9 million, up 83.92% over the prior year.
- Other Gross PP&E Adjustments was -$5.5 million for Q3 2025 at CytomX Therapeutics, up from -$7.3 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $9.9 million in Q4 2024 and bottomed at -$23.0 million in Q2 2021.
- Average Other Gross PP&E Adjustments over 5 years is -$12.2 million, with a median of -$12.4 million recorded in 2024.
- The sharpest move saw Other Gross PP&E Adjustments tumbled 194.12% in 2021, then skyrocketed 147.88% in 2023.
- Year by year, Other Gross PP&E Adjustments stood at -$7.4 million in 2021, then plummeted by 52.36% to -$11.2 million in 2022, then surged by 147.88% to $5.4 million in 2023, then soared by 83.92% to $9.9 million in 2024, then tumbled by 156.2% to -$5.5 million in 2025.
- Business Quant data shows Other Gross PP&E Adjustments for CTMX at -$5.5 million in Q3 2025, -$7.3 million in Q2 2025, and -$8.0 million in Q1 2025.